Loading patent…
AssigneeApeiron Biologics AG
InventorsHans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
Estimating the term…
The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2 wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.
A method of treating a GD2 positive cancer in a patient comprising administering a preparation comprising an anti-GD2 antibody to the patient without concomitantly administering IL-2 within the same treatment cycle and/or within the same overall treatment period, wherein a GD2 positive cancer is treated in the patient, wherein the anti-GD2 antibody is a 14.18 antibody, and wherein the preparation is administered to the patient in a dose of 10 mg/m2/day for 10 consecutive days or in a dose of 15, 20, or 25 mg/m2/day for 4 consecutive days.
Dependencies are inferred from the claim text.